SeraNovo

SeraNovo is a specialized drug delivery company addressing the critical industry challenge of poor oral bioavailability. Its core technology, NanoGlass™, generates and stabilizes amorphous nanoparticles of active pharmaceutical ingredients (APIs) in situ, significantly enhancing solubility, dissolution, and absorption. The company operates as a service and platform provider, offering rapid feasibility studies and formulation development for biotech and pharmaceutical partners, with a focus on complex modalities like protein degraders. Based in Leiden, it is a private, likely pre-revenue entity supporting the development pipelines of its clients.

NanoGlass™: A suite of four proprietary formulation platforms (GlassE, GlassA, HyGlass, LiGlass) that generate and stabilize amorphous nanoparticles of APIs in situ to maximize thermodynamic activity, solubility, and oral bioavailability for poorly soluble drugs.

SeraNovo competes with other specialized drug delivery firms and large CROs offering formulation services. Its key differentiation is the focused NanoGlass™ platform for amorphous nanoparticles and its emphasis on rapid, in vivo-proven feasibility for the most challenging molecules, particularly protein degraders.